Last reviewed: July 2, 2026
Last updated: July 2, 2026
Written by:
Jay Hastings,
CEO of PlexusDx
Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.
Medically reviewed by:
Jayden Lee, PharmD, EMBA
Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.
This article is part of the PlexusDx Education Hub — science-backed guidance on GLP-1 medications, metabolic health, and precision weight management.
Patients often ask whether Wegovy or Ozempic is the better choice for weight loss, but the answer may surprise you: both medications contain identical active ingredients. The real difference lies in marketing, insurance coverage, and cost. PlexusDx provides a third option through licensed 503A compounding pharmacies that delivers the same therapeutic benefits at a fraction of the price.
Understanding the Difference Between Wegovy and Ozempic
Wegovy and Ozempic both contain semaglutide, a GLP-1 receptor agonist that slows stomach emptying and reduces hunger signals in the brain. The FDA approved Ozempic in 2017 for type 2 diabetes management, while Wegovy received approval in 2021 specifically for chronic weight management in adults with obesity or overweight with weight-related conditions. Despite identical active ingredients, pharmaceutical companies market these products separately, creating confusion about their actual differences.
The distinction between them is purely regulatory and commercial, not chemical. Ozempic comes in lower starting doses (0.25 mg weekly) and is labeled for diabetes, though doctors frequently prescribe it off-label for weight loss. Wegovy begins at the same 0.25 mg weekly dose but is explicitly branded and marketed as a weight-loss treatment, allowing pharmaceutical companies to charge premium prices. Insurance coverage varies dramatically: some plans cover Ozempic for diabetes but deny Wegovy for weight loss, even though the medication is identical.
Pricing and Insurance Coverage Differences
Retail Wegovy typically costs $900–$1,300 per month without insurance, while Ozempic for weight loss is similarly expensive due to brand-name pricing structures. Patients with diabetes insurance may see lower out-of-pocket costs for Ozempic because it's an approved diabetes medication, but insurance rarely covers either drug for primary weight management. Prior authorization requirements, coverage gaps, and plan exclusions create additional barriers that delay treatment initiation or force patients to abandon therapy.
PlexusDx compounded semaglutide injection starts at $149 per month and requires no insurance, no membership fees, and no prior authorization. The cost remains flat regardless of dose escalation—your dose may need to go up, but your price won't. HSA and FSA accounts are eligible, making the treatment accessible to patients who have been priced out of brand-name alternatives. This pricing model removes financial barriers while maintaining pharmaceutical-grade quality through licensed 503A compounding pharmacies.
Clinical Efficacy: Is One Better Than the Other?
Both Wegovy and Ozempic produce identical weight-loss outcomes when the same doses are used, because they contain the same drug at the same strength. Clinical trials of semaglutide for weight loss show average weight reduction of 15–22% over 68 weeks at the highest doses (2.4 mg weekly), with patients maintaining an average 10% weight loss at 104 weeks. Efficacy depends on dose, duration of treatment, patient adherence, lifestyle factors, and individual metabolic response—not on whether the medication carries a Wegovy or Ozempic label.
Real-world effectiveness varies based on whether patients have genetic predispositions that affect GLP-1 receptor sensitivity and peptide-pathway responsiveness. The PlexusDx Precision Peptide Genetic Test ($99 add-on) analyzes 14 metabolic pathways and 49 peptides, including key variants like GLP1R rs6923761, to identify which compounds—semaglutide, tirzepatide, or combination therapies—are most likely to produce optimal results for each individual. This personalization step transforms weight loss from a one-size-fits-all approach into a precision-medicine strategy.
Why Compounded Semaglutide Is a Smarter Alternative
Compounded semaglutide from licensed 503A pharmacies meets the same pharmaceutical standards as brand-name Wegovy and Ozempic, with identical active ingredients and bioequivalent delivery. The term 503A refers to traditional compounding pharmacies regulated by state boards and federal law; PlexusDx partners exclusively with these licensed facilities, never with 503B outsourcing vendors. Quality, sterility, and potency are verified through rigorous testing protocols that match or exceed manufacturing requirements for FDA-approved medications.
Choosing compounded semaglutide eliminates the markup associated with brand-name marketing, advertising, and distribution channels. PlexusDx passes these savings directly to patients while maintaining the same clinical outcomes. Starting at $149 per month with no insurance requirement, compounded semaglutide makes GLP-1 therapy accessible to patients who would otherwise delay treatment due to cost barriers. This affordability does not compromise safety, efficacy, or the quality of the therapeutic experience.
Choosing Between Semaglutide, Tirzepatide, and Dual-Compound Protocols
While semaglutide is the active ingredient in both Wegovy and Ozempic, PlexusDx offers additional options tailored to individual patient needs. Tirzepatide (marketed as Zepbound and Mounjaro) is a dual GLP-1/GIP receptor agonist that engages two appetite-regulation pathways simultaneously, often producing 20–25% weight loss versus 15–22% with semaglutide alone. PlexusDx compounded tirzepatide injection starts at $249 per month, offering the same affordability advantage over brand names without requiring insurance.
For patients seeking maximum efficacy, PlexusDx GLP-Squared injection combines semaglutide and tirzepatide in a single weekly injection, targeting multiple peptide pathways simultaneously while maintaining flat pricing at $249 per month. The Precision Peptide Genetic Test helps identify whether patients will respond better to single-agent semaglutide, tirzepatide, or the dual-compound approach based on their individual metabolic genetics. This data-driven selection process replaces trial-and-error prescribing with evidence-based personalization.
How Your Genetics Influence GLP-1 Response
Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, GLP1R rs6923761, FTO rs9939609, and MC4R rs17782313 — influence how your body processes these medications, how much weight you lose, and how you tolerate side effects. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights to match each patient to the right medication, dose, and lifestyle protocol for their biology. The PlexusDx Precision Peptide Genetic Test ($99 add-on after your first month of treatment) gives your provider precise insight into your peptide genetic predispositions before the first prescription is written.
Access Personalized GLP-1 Care Through PlexusDx
PlexusDx offers six prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Semaglutide Injection starts at $149/mo. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test for $99 to personalize your protocol from day one.
Frequently Asked Questions
Is Wegovy the same as Ozempic?
Yes, Wegovy and Ozempic contain identical semaglutide at the same strength, but they're marketed separately for different indications. Ozempic is labeled for diabetes, while Wegovy is labeled for weight loss. PlexusDx compounded semaglutide injection provides the same active ingredient starting at $149 per month without insurance requirements.
Does semaglutide actually work for weight loss?
Clinical trials show semaglutide produces average weight reduction of 15–22% over 68 weeks at highest doses (2.4 mg weekly). Real-world results vary based on dose, adherence, lifestyle, and individual metabolic genetics. PlexusDx Precision Peptide Genetic Testing can predict your likely response to semaglutide based on GLP1R and other metabolic variants.
Why is Wegovy so expensive compared to PlexusDx compounded semaglutide?
Brand-name Wegovy costs $900–$1,300 monthly due to pharmaceutical marketing, advertising, and distribution markups. PlexusDx compounded semaglutide provides identical medication from licensed 503A pharmacies at $149 per month—eliminating brand overhead while maintaining pharmaceutical-grade quality. No insurance is required, and pricing remains flat regardless of dose increases.
Are compounded medications as safe as FDA-approved Wegovy?
PlexusDx compounded semaglutide is manufactured by licensed 503A compounding pharmacies that meet rigorous federal and state quality standards. While compounded medications are not FDA-approved, they contain identical active ingredients with verified potency and sterility. Safety and efficacy depend on proper dosing, medical supervision, and individual health status—not on whether medication is brand-name or compounded.
How does the Precision Peptide Genetic Test help me choose between semaglutide and tirzepatide?
The PlexusDx Precision Peptide Genetic Test ($99 add-on) analyzes genetic variants in GLP1R, GIPR, FTO, and MC4R pathways to predict your metabolic response. Patients with stronger GLP1R activation may optimize with semaglutide, while those with more GIPR sensitivity often respond better to tirzepatide. This test eliminates guesswork and personalizes your treatment to your genetic profile.
Related Reading
Pricing and availability current as of July 2026. Compounded GLP-1 medications are not FDA-approved drug products; they are prepared by licensed compounding pharmacies under federal compounding regulations. Compounded semaglutide and tirzepatide are not the same as Wegovy, Ozempic, Zepbound, or Mounjaro. This article is for informational purposes only and does not constitute medical advice. Consult a licensed healthcare provider before starting, stopping, or changing any medication.
Return to the PlexusDx Education Hub for more evidence-based resources on GLP-1 therapy, metabolic health, and personalized weight management.
Medical and Editorial Standards
Medical review process: This article was reviewed for medical accuracy, scientific clarity, evidence alignment, and appropriate discussion of genetics, medications, supplements, biomarkers, and health-related claims.
Sources and evidence: PlexusDx educational content is developed using peer-reviewed research, clinical literature, reputable medical references, and, where applicable, public health or regulatory guidance.
Commercial transparency: PlexusDx offers genetic testing, blood biomarker testing, personalized supplement recommendations, and related precision wellness services. Product mentions are intended to help readers understand available options and should not be interpreted as medical advice.
Important disclaimer: PlexusDx educational content is for informational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making decisions about medications, supplements, genetic testing, lab testing, or health-related care.
Share:
Mastering Your Weight Loss Journey: A Deep Dive into How the Ozempic® Pen Works
How Much Weight Per Week Do You Lose on Zepbound?